<i>ESR1</i> Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor–Positive Breast Cancer
Chang‐Ching Lin, María del Rosario Chica-Parrado, Nisha Unni, Ellen Jaeger, Yisheng Fang, Lei Guo, Fabiana Napolitano, Pamela Luna, Michelle Harris, Calvin Chao, Lin Xu, Carlos L. Arteaga, Ariella B. Hanker
Abstract
PURPOSE: Breast cancers with ESR1 mutations are resistant to antiestrogen therapy. In this study, we aimed to investigate the association of ESR1 mutations with resistance to CDK4/6 inhibitors (CDK4/6i) using real-world data analysis and experimental validation. EXPERIMENTAL DESIGN: A total of 3,958 patients with estrogen receptor-positive metastatic breast cancer with DNA sequencing data were analyzed. Breast tumor DNA and ctDNA were sequenced using the Tempus xT tumor assay and Tempus xF liquid biopsy, respectively. Patients were stratified into either treated with CDK4/6i (tumor tissue: 1,070; ctDNA: 1,885) or CDK4/6i naïve (tumor tissue: 750; ctDNA: 253). Engineered MCF7 cells carrying ESR1Y537S or ESR1D538G knock-in mutations were used to study antitumor efficacy of the CDK4/6i palbociclib in vitro and in vivo. RESULTS: In both xF and xT assays, ESR1 mutations were the only somatic alterations significantly more frequent in patients who received CDK4/6i compared with those who did not. Knock-in of ESR1Y537S or ESR1D538G in MCF7 cells resulted in upregulation of cell cycle-related gene signatures upon treatment with CDK4/6i ± antiestrogen compared with cells with nonmutant ESR1. MCF7 xenografts harboring ESR1Y537S and ESR1D538G mutations established in nude mice were resistant to palbociclib. CONCLUSIONS: We report herein real-world and preclinical evidence that ESR1 mutations, particularly Y537S and D538G, can drive resistance to CDK4/6i.